عنصر الكروم في أيض الجلوكوز (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "عنصر الكروم في أيض الجلوكوز" in Arabic language version.

refsWebsite

Global rank Arabic rank

11doi.org

2^nd place

5^th place

10nih.gov

4^th place

6^th place

2web.archive.org

1^st place

1archive-it.org

910^th place

1,495^th place

1hc-sc.gc.ca

low place

4,231^st place

1worldcat.org

5^th place

4^th place

archive-it.org

wayback.archive-it.org

FDA Qualified Health Claims: Letters of Enforcement Discretion, Letters of Denial U.S. Food and Drug Administration, Docket #2004Q-0144 (August 2005). نسخة محفوظة 2023-04-08 على موقع واي باك مشين.

doi.org

Guerrero-Romero، F؛ Rodríguez-Morán، M (2005). "Complementary Therapies for Diabetes: The Case for Chromium, Magnesium, and Antioxidants". Archives of Medical Research. ج. 36 ع. 3: 250–257. DOI:10.1016/j.arcmed.2005.01.004. PMID:15925015.
Lay، Peter A. (2012). "Chromium: Biological Relevance". "Chromium: biological relevance" in "Encyclopedia of Inorganic and Bioinorganic Chemistry. John Wiley & Sons. DOI:10.1002/9781119951438.eibc0040. ISBN:9781119951438.
Cefalu، W. T.؛ Hu، F. B. (2004). "Role of chromium in human health and in diabetes". Diabetes Care. ج. 27 ع. 11: 2741–2751. DOI:10.2337/diacare.27.11.2741. PMID:15505017.
Schwarz، K؛ Mertz، W (1959). "Chromium(III) and the glucose tolerance factor". Archives of Biochemistry and Biophysics. ج. 85: 292–295. DOI:10.1016/0003-9861(59)90479-5. PMID:14444068.
"Scientific Opinion on the substantiation of health claims related to chromium and contribution to normal macronutrient metabolism (ID 260, 401, 4665, 4666, 4667), maintenance of normal blood glucose concentrations (ID 262, 4667), contribution to the maintenance or achievement of a normal body weight (ID 339, 4665, 4666), and reduction of tiredness and fatigue (ID 261) pursuant to Article 13(1) of Regulation (EC) No 1924/2006". EFSA Journal (بالإنجليزية). 8 (10). Oct 2010. DOI:10.2903/j.efsa.2010.1732. ISSN:1831-4732.
Costello RB، Dwyer JT، Bailey RL (2016). "Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness". Nutr. Rev. ج. 74 ع. 7: 455–468. DOI:10.1093/nutrit/nuw011. PMC:5009459. PMID:27261273.
San Mauro-Martin I, Ruiz-León AM, et al. (2016). "[Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials]". Nutr Hosp (بالإسبانية). 33 (1): 27. DOI:10.20960/nh.27. PMID:27019254.
Abdollahi M، Farshchi A، Nikfar S، Seyedifar M (2013). "Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials". J Pharm Pharm Sci. ج. 16 ع. 1: 99–114. DOI:10.18433/J3G022. PMID:23683609.
Suksomboon N، Poolsup N، Yuwanakorn A (2014). "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes". J Clin Pharm Ther. ج. 39 ع. 3: 292–306. DOI:10.1111/jcpt.12147. PMID:24635480.
Vincent، J. B. (2000). "Elucidating a biological role for chromium at a molecular level". Accounts of Chemical Research. ج. 33 ع. 7: 503–510. DOI:10.1021/ar990073r. PMID:10913239.
Vincent، J. B. (2000). "The biochemistry of chromium". The Journal of Nutrition. ج. 130 ع. 4: 715–718. DOI:10.1093/jn/130.4.715. PMID:10736319.

hc-sc.gc.ca

webprod.hc-sc.gc.ca

"Monograph: Chromium (from Chromium picolinate)". Health Canada. 9 ديسمبر 2009. مؤرشف من الأصل في 2022-01-26. اطلع عليه بتاريخ 2015-03-24.

nih.gov

pubmed.ncbi.nlm.nih.gov

Guerrero-Romero، F؛ Rodríguez-Morán، M (2005). "Complementary Therapies for Diabetes: The Case for Chromium, Magnesium, and Antioxidants". Archives of Medical Research. ج. 36 ع. 3: 250–257. DOI:10.1016/j.arcmed.2005.01.004. PMID:15925015.
Cefalu، W. T.؛ Hu، F. B. (2004). "Role of chromium in human health and in diabetes". Diabetes Care. ج. 27 ع. 11: 2741–2751. DOI:10.2337/diacare.27.11.2741. PMID:15505017.
Schwarz، K؛ Mertz، W (1959). "Chromium(III) and the glucose tolerance factor". Archives of Biochemistry and Biophysics. ج. 85: 292–295. DOI:10.1016/0003-9861(59)90479-5. PMID:14444068.
Costello RB، Dwyer JT، Bailey RL (2016). "Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness". Nutr. Rev. ج. 74 ع. 7: 455–468. DOI:10.1093/nutrit/nuw011. PMC:5009459. PMID:27261273.
San Mauro-Martin I, Ruiz-León AM, et al. (2016). "[Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials]". Nutr Hosp (بالإسبانية). 33 (1): 27. DOI:10.20960/nh.27. PMID:27019254.
Abdollahi M، Farshchi A، Nikfar S، Seyedifar M (2013). "Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials". J Pharm Pharm Sci. ج. 16 ع. 1: 99–114. DOI:10.18433/J3G022. PMID:23683609.
Suksomboon N، Poolsup N، Yuwanakorn A (2014). "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes". J Clin Pharm Ther. ج. 39 ع. 3: 292–306. DOI:10.1111/jcpt.12147. PMID:24635480.
Vincent، J. B. (2000). "Elucidating a biological role for chromium at a molecular level". Accounts of Chemical Research. ج. 33 ع. 7: 503–510. DOI:10.1021/ar990073r. PMID:10913239.
Vincent، J. B. (2000). "The biochemistry of chromium". The Journal of Nutrition. ج. 130 ع. 4: 715–718. DOI:10.1093/jn/130.4.715. PMID:10736319.

ncbi.nlm.nih.gov

Costello RB، Dwyer JT، Bailey RL (2016). "Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness". Nutr. Rev. ج. 74 ع. 7: 455–468. DOI:10.1093/nutrit/nuw011. PMC:5009459. PMID:27261273.

web.archive.org

FDA Qualified Health Claims: Letters of Enforcement Discretion, Letters of Denial U.S. Food and Drug Administration, Docket #2004Q-0144 (August 2005). نسخة محفوظة 2023-04-08 على موقع واي باك مشين.
"Monograph: Chromium (from Chromium picolinate)". Health Canada. 9 ديسمبر 2009. مؤرشف من الأصل في 2022-01-26. اطلع عليه بتاريخ 2015-03-24.

worldcat.org

"Scientific Opinion on the substantiation of health claims related to chromium and contribution to normal macronutrient metabolism (ID 260, 401, 4665, 4666, 4667), maintenance of normal blood glucose concentrations (ID 262, 4667), contribution to the maintenance or achievement of a normal body weight (ID 339, 4665, 4666), and reduction of tiredness and fatigue (ID 261) pursuant to Article 13(1) of Regulation (EC) No 1924/2006". EFSA Journal (بالإنجليزية). 8 (10). Oct 2010. DOI:10.2903/j.efsa.2010.1732. ISSN:1831-4732.